NYSE:CNMD

CONMED Competitors

$143.24
-0.41 (-0.29 %)
(As of 05/10/2021 12:00 AM ET)
Add
Compare
Today's Range
$142.30
$146.46
50-Day Range
$120.87
$145.09
52-Week Range
$60.65
$146.95
Volume332,125 shs
Average Volume289,344 shs
Market Capitalization$4.17 billion
P/E RatioN/A
Dividend Yield0.56%
Beta1.55

Competitors

CONMED (NYSE:CNMD) Vs. VAR, MASI, LIVN, INMD, OM, and BLFS

Should you be buying CNMD stock or one of its competitors? Companies in the industry of "electromedical equipment" are considered alternatives and competitors to CONMED, including Varian Medical Systems (VAR), Masimo (MASI), LivaNova (LIVN), InMode (INMD), Outset Medical (OM), and BioLife Solutions (BLFS).

CONMED (NYSE:CNMD) and Varian Medical Systems (NYSE:VAR) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their risk, earnings, valuation, analyst recommendations, institutional ownership, profitability and dividends.

Profitability

This table compares CONMED and Varian Medical Systems' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
CONMED0.04%9.48%3.75%
Varian Medical Systems8.50%18.45%8.08%

Valuation & Earnings

This table compares CONMED and Varian Medical Systems' gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
CONMED$955.10 million4.36$28.62 million$2.6454.26
Varian Medical Systems$3.17 billion5.13$269.20 million$3.9145.29

Varian Medical Systems has higher revenue and earnings than CONMED. Varian Medical Systems is trading at a lower price-to-earnings ratio than CONMED, indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

CONMED has a beta of 1.55, suggesting that its share price is 55% more volatile than the S&P 500. Comparatively, Varian Medical Systems has a beta of 1.06, suggesting that its share price is 6% more volatile than the S&P 500.

Institutional and Insider Ownership

87.0% of Varian Medical Systems shares are held by institutional investors. 5.4% of CONMED shares are held by insiders. Comparatively, 0.8% of Varian Medical Systems shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Analyst Ratings

This is a summary of current recommendations and price targets for CONMED and Varian Medical Systems, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
CONMED01202.67
Varian Medical Systems15001.83

CONMED presently has a consensus target price of $117.3333, indicating a potential downside of 18.09%. Varian Medical Systems has a consensus target price of $177.70, indicating a potential upside of 0.36%. Given Varian Medical Systems' higher probable upside, analysts clearly believe Varian Medical Systems is more favorable than CONMED.

Summary

Varian Medical Systems beats CONMED on 10 of the 14 factors compared between the two stocks.

Masimo (NASDAQ:MASI) and CONMED (NYSE:CNMD) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their valuation, profitability, institutional ownership, analyst recommendations, risk, earnings and dividends.

Profitability

This table compares Masimo and CONMED's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Masimo20.30%15.75%13.12%
CONMED0.04%9.48%3.75%

Valuation and Earnings

This table compares Masimo and CONMED's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Masimo$937.84 million12.72$196.22 million$3.2267.35
CONMED$955.10 million4.36$28.62 million$2.6454.26

Masimo has higher earnings, but lower revenue than CONMED. CONMED is trading at a lower price-to-earnings ratio than Masimo, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of recent ratings and recommmendations for Masimo and CONMED, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Masimo02402.67
CONMED01202.67

Masimo currently has a consensus price target of $291.50, indicating a potential upside of 34.41%. CONMED has a consensus price target of $117.3333, indicating a potential downside of 18.09%. Given Masimo's higher probable upside, research analysts clearly believe Masimo is more favorable than CONMED.

Volatility & Risk

Masimo has a beta of 0.87, meaning that its share price is 13% less volatile than the S&P 500. Comparatively, CONMED has a beta of 1.55, meaning that its share price is 55% more volatile than the S&P 500.

Institutional and Insider Ownership

81.6% of Masimo shares are owned by institutional investors. 11.5% of Masimo shares are owned by insiders. Comparatively, 5.4% of CONMED shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Summary

Masimo beats CONMED on 11 of the 13 factors compared between the two stocks.

LivaNova (NASDAQ:LIVN) and CONMED (NYSE:CNMD) are both mid-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their dividends, institutional ownership, risk, earnings, profitability, analyst recommendations and valuation.

Earnings & Valuation

This table compares LivaNova and CONMED's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
LivaNova$1.08 billion3.74$-155,180,000.00$3.0826.92
CONMED$955.10 million4.36$28.62 million$2.6454.26

CONMED has lower revenue, but higher earnings than LivaNova. LivaNova is trading at a lower price-to-earnings ratio than CONMED, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares LivaNova and CONMED's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
LivaNova-21.88%5.55%3.07%
CONMED0.04%9.48%3.75%

Institutional and Insider Ownership

89.1% of LivaNova shares are held by institutional investors. 0.5% of LivaNova shares are held by company insiders. Comparatively, 5.4% of CONMED shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Analyst Recommendations

This is a breakdown of recent ratings and target prices for LivaNova and CONMED, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
LivaNova02202.50
CONMED01202.67

LivaNova currently has a consensus target price of $87.75, indicating a potential upside of 5.85%. CONMED has a consensus target price of $117.3333, indicating a potential downside of 18.09%. Given LivaNova's higher possible upside, analysts clearly believe LivaNova is more favorable than CONMED.

Volatility & Risk

LivaNova has a beta of 0.8, indicating that its share price is 20% less volatile than the S&P 500. Comparatively, CONMED has a beta of 1.55, indicating that its share price is 55% more volatile than the S&P 500.

Summary

CONMED beats LivaNova on 8 of the 13 factors compared between the two stocks.

CONMED (NYSE:CNMD) and InMode (NASDAQ:INMD) are both mid-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, risk, analyst recommendations, profitability, dividends, valuation and earnings.

Earnings & Valuation

This table compares CONMED and InMode's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
CONMED$955.10 million4.36$28.62 million$2.6454.26
InMode$156.36 million14.83$61.15 million$1.6045.33

InMode has lower revenue, but higher earnings than CONMED. InMode is trading at a lower price-to-earnings ratio than CONMED, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares CONMED and InMode's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
CONMED0.04%9.48%3.75%
InMode32.57%28.56%24.14%

Institutional & Insider Ownership

35.7% of InMode shares are held by institutional investors. 5.4% of CONMED shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Analyst Recommendations

This is a summary of current recommendations for CONMED and InMode, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
CONMED01202.67
InMode00403.00

CONMED presently has a consensus price target of $117.3333, indicating a potential downside of 18.09%. InMode has a consensus price target of $80.25, indicating a potential upside of 10.66%. Given InMode's stronger consensus rating and higher possible upside, analysts clearly believe InMode is more favorable than CONMED.

Volatility & Risk

CONMED has a beta of 1.55, suggesting that its stock price is 55% more volatile than the S&P 500. Comparatively, InMode has a beta of 1.95, suggesting that its stock price is 95% more volatile than the S&P 500.

Summary

InMode beats CONMED on 11 of the 14 factors compared between the two stocks.

CONMED (NYSE:CNMD) and Outset Medical (NASDAQ:OM) are both mid-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, risk, analyst recommendations, profitability, dividends, valuation and earnings.

Earnings & Valuation

This table compares CONMED and Outset Medical's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
CONMED$955.10 million4.36$28.62 million$2.6454.26
Outset MedicalN/AN/AN/AN/AN/A

CONMED has higher revenue and earnings than Outset Medical.

Profitability

This table compares CONMED and Outset Medical's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
CONMED0.04%9.48%3.75%
Outset MedicalN/AN/AN/A

Institutional & Insider Ownership

84.6% of Outset Medical shares are held by institutional investors. 5.4% of CONMED shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Analyst Recommendations

This is a summary of current recommendations for CONMED and Outset Medical, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
CONMED01202.67
Outset Medical03502.63

CONMED presently has a consensus price target of $117.3333, indicating a potential downside of 18.09%. Outset Medical has a consensus price target of $58.20, indicating a potential upside of 18.17%. Given Outset Medical's higher possible upside, analysts clearly believe Outset Medical is more favorable than CONMED.

Summary

CONMED beats Outset Medical on 6 of the 9 factors compared between the two stocks.

CONMED (NYSE:CNMD) and BioLife Solutions (NASDAQ:BLFS) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, dividends, valuation, analyst recommendations, profitability, earnings and risk.

Profitability

This table compares CONMED and BioLife Solutions' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
CONMED0.04%9.48%3.75%
BioLife Solutions12.67%0.53%0.43%

Earnings and Valuation

This table compares CONMED and BioLife Solutions' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
CONMED$955.10 million4.36$28.62 million$2.6454.26
BioLife Solutions$27.37 million38.07$-1,660,000.00$0.08386.25

CONMED has higher revenue and earnings than BioLife Solutions. CONMED is trading at a lower price-to-earnings ratio than BioLife Solutions, indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

CONMED has a beta of 1.55, suggesting that its share price is 55% more volatile than the S&P 500. Comparatively, BioLife Solutions has a beta of 1.55, suggesting that its share price is 55% more volatile than the S&P 500.

Analyst Ratings

This is a breakdown of current ratings for CONMED and BioLife Solutions, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
CONMED01202.67
BioLife Solutions01902.90

CONMED presently has a consensus price target of $117.3333, indicating a potential downside of 18.09%. BioLife Solutions has a consensus price target of $46.6667, indicating a potential upside of 51.02%. Given BioLife Solutions' stronger consensus rating and higher possible upside, analysts clearly believe BioLife Solutions is more favorable than CONMED.

Institutional and Insider Ownership

67.7% of BioLife Solutions shares are owned by institutional investors. 5.4% of CONMED shares are owned by insiders. Comparatively, 22.3% of BioLife Solutions shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Summary

BioLife Solutions beats CONMED on 8 of the 13 factors compared between the two stocks.


CONMED Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Varian Medical Systems logo
VAR
Varian Medical Systems
1.3$177.07-0.0%$16.26 billion$3.17 billion60.43
Masimo logo
MASI
Masimo
1.8$216.88-3.4%$11.93 billion$937.84 million56.33
LivaNova logo
LIVN
LivaNova
1.5$82.90-0.1%$4.05 billion$1.08 billion-19.28
InMode logo
INMD
InMode
1.7$72.52-6.3%$2.32 billion$156.36 million52.17Earnings Announcement
Outset Medical logo
OM
Outset Medical
1.3$49.25-6.0%$2.12 billionN/A0.00Earnings Announcement
Analyst Downgrade
BioLife Solutions logo
BLFS
BioLife Solutions
2.1$30.90-2.5%$1.04 billion$27.37 million-42.33Upcoming Earnings
NTUS
Natus Medical
1.1$27.40-2.8%$934.20 million$495.52 million-49.82Earnings Announcement
AxoGen logo
AXGN
AxoGen
1.5$21.78-7.9%$888.01 million$106.71 million-34.57Earnings Announcement
ViewRay logo
VRAY
ViewRay
1.3$5.19-4.8%$839.43 million$87.78 million-5.83Earnings Announcement
TransMedics Group logo
TMDX
TransMedics Group
1.6$23.13-4.8%$638.92 million$23.60 million-16.52Earnings Announcement
Cutera logo
CUTR
Cutera
1.3$30.43-4.8%$541.81 million$181.71 million-16.81Earnings Announcement
Zynex logo
ZYXI
Zynex
1.8$14.09-2.3%$490.99 million$45.47 million42.70
Edap Tms logo
EDAP
Edap Tms
1.3$6.49-3.1%$189.28 million$50.23 million-108.17
Second Sight Medical Products logo
EYES
Second Sight Medical Products
0.8$5.16-7.6%$144.01 million$3.38 million-2.70Gap Down
IRIDEX logo
IRIX
IRIDEX
0.9$7.48-4.3%$116.88 million$43.45 million-13.60
FONR
FONAR
1.1$17.09-0.6%$112.01 million$85.69 million16.12
BioSig Technologies logo
BSGM
BioSig Technologies
0.5$2.94-9.2%$94.50 millionN/A0.00
ENDRA Life Sciences logo
NDRA
ENDRA Life Sciences
0.6$2.07-4.8%$86.20 million$10,000.00-1.12Upcoming Earnings
Gap Down
Soleno Therapeutics logo
SLNO
Soleno Therapeutics
1.9$1.08-2.8%$86.10 millionN/A-1.42Earnings Announcement
Gap Down
electroCore logo
ECOR
electroCore
1.4$1.70-11.8%$82.52 million$2.39 million-2.15Earnings Announcement
Gap Up
Helius Medical Technologies logo
HSDT
Helius Medical Technologies
1.3$15.15-2.4%$35.10 million$1.50 million-0.87Upcoming Earnings
News Coverage
Viveve Medical logo
VIVE
Viveve Medical
0.9$2.66-4.1%$27.51 million$6.57 million-0.01Upcoming Earnings
Gap Down
Nuwellis logo
CHFS
Nuwellis
1.7$4.55-1.1%$27.47 million$5.51 million-0.09
Star Equity logo
STRR
Star Equity
0.1$2.84-0.4%$13.98 million$114.18 million-0.90Upcoming Earnings
News Coverage
Gap Up
This page was last updated on 5/11/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.